Kedrab Market Report 2026

Kedrab Market Overview

• The Kedrab market growth in the historic period has been driven by high rabies fatality rates, reliance on immunoglobulin products • Market expansion is supported by increasing animal bite incidents, expansion of rabies awareness campaigns • Growth Driver: Rise In Rabies Cases Fuels Market Growth • Market Trend: Kedrab U.S. Distribution Extended Through Exclusive Licensing Agreement To Strengthen Market Presence • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Kedrab Market?

Kedrab is a monoclonal antibody used for the prevention and treatment of rabies following potential exposure to the virus. It is derived from human sources and is designed to provide passive immunity by neutralizing the rabies virus, helping to prevent the onset of disease when administered after exposure. The main indications of kedrab are post-exposure prophylaxis for rabies and treatment for patients exposed to suspected rabid animals. Post-exposure prophylaxis (PEP) for rabies involves immediate wound cleansing, administration of rabies immunoglobulin, and a series of rabies vaccinations to prevent virus progression after exposure. The various formulations are injectable formulations and lyophilized powders for reconstitution, and the routes of administration are intramuscular injection and subcutaneous injection. The distribution channels are direct sales, wholesalers and distributors, retail pharmacies, and online pharmacies, and it is used by various end users such as hospitals, emergency departments, specialty clinics, and public health organizations.

What Is The Kedrab Market Growth Forecast?

The growth in the forecast period can be attributed to increasing animal bite incidents, expansion of rabies awareness campaigns, growth in emergency care infrastructure, improved access to monoclonal antibodies, rising government investment in rabies prevention. Major trends in the forecast period include growing use of rabies passive immunization, expansion of post exposure prophylaxis programs, rising focus on zoonotic disease control, increased emergency immunotherapy demand, strengthening public health response systems.

Global Kedrab Market Segmentation

1) By Indication: Post-Exposure Prophylaxis For Rabies, Treatment For Patients Exposed To Suspected Rabid Animals 2) By Formulation: Injectable Formulation, Lyophilized Powder For Reconstitution 3) By Route Of Administration: Intramuscular Injection, Subcutaneous Injection 4) By Distribution Channel: Direct Sales, Wholesalers And Distributors, Retail Pharmacies, Online Pharmacies 5) By End User: Hospitals, Emergency Departments, Specialty Clinics, Public Health Organizations

What Is The Driver Of The Kedrab Market?

The increasing incidence of rabies is expected to drive the kedrab market going forward. Rabies is a nearly always fatal disease caused by exposure to rabid animals, posing a critical public health concern, particularly in regions with limited access to vaccines. The increasing incidence of rabies is driven by inadequate vaccination of domestic animals, limited access to post-exposure prophylaxis, and the prevalence of rabies in wildlife, particularly in underserved regions. Kedrab is a human rabies immunoglobulin used for immediate passive immunity in individuals exposed to the rabies virus, providing critical protection until active immunity develops through vaccination. For instance, in April 2024, according to the South Dakota Department of Health, a US-based government agency, in 2023, around 20 animals in South Dakota were confirmed to have rabies, showing a 122% increase from the 9 cases reported in 2022. Therefore, the increasing incidence of rabies drives the kedrab industry.

Key Players In The Global Kedrab Market

Major companies operating in the kedrab market are Kamada Ltd., Kedrion Biopharma Inc.

Global Kedrab Market Trends and Insights

Major companies are operating in the kedrab market, focusing on development of innovative solutions and securing regulatory such as exclusive licensing and distribution continuation notice to enhance kedrab u.s. commercial reach and market presence. An exclusive licensing and distribution continuation notice is an official communication issued by a pharmaceutical or biotechnology company to announce that an existing agreement granting exclusive rights to license, distribute, or commercialize a specific product has been extended or renewed. For instance, in July 2023, Kamada Ltd., an Israel-based plasma-derived biopharmaceutical company, announced that Kedrion Biopharma exercised its option to extend the exclusive U.S. distribution agreement for KEDRAB, a human rabies immune globulin used for post-exposure prophylaxis. KEDRAB provides immediate passive immunity against rabies following potential exposure, with established efficacy, safety, and regulatory approval in the U.S. The two-year extension ensures continued availability and supply stability, supporting Kedrion’s commercial distribution infrastructure and strategic presence in the U.S. immunoglobulin market enhancing patient access and public health preparedness.

What Are Latest Mergers And Acquisitions In The Kedrab Market?

In December 2023, Kedrion Biopharma, an Italy-based biopharmaceutical company, partnered with Kamada to enhance their distribution agreement for KEDRAB, a human rabies immune globulin (HRIG). This collaboration emphasizes Kedrion's continued commitment to providing vital therapies derived from hyperimmune plasma and its strategic focus on expanding its market presence in the fight against rabies and other critical diseases. Kamada Ltd. is an Israel-based biopharmaceutical company.

Regional Insights

North America was the largest region in the kedrab market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

What Defines the Kedrab Market?

The kedrab market consists of sales of kedrab-related biopharmaceutical products, including plasma-derived therapies and other related treatments. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Kedrab Market Report 2026?

The kedrab market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the kedrab industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.